301 related articles for article (PubMed ID: 18855533)
1. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Limdi NA; Beasley TM; Crowley MR; Goldstein JA; Rieder MJ; Flockhart DA; Arnett DK; Acton RT; Liu N
Pharmacogenomics; 2008 Oct; 9(10):1445-58. PubMed ID: 18855533
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
Limdi NA; Arnett DK; Goldstein JA; Beasley TM; McGwin G; Adler BK; Acton RT
Pharmacogenomics; 2008 May; 9(5):511-26. PubMed ID: 18466099
[TBL] [Abstract][Full Text] [Related]
3. New genetic variant that might improve warfarin dose prediction in African Americans.
Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
[TBL] [Abstract][Full Text] [Related]
5. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation.
Geisen C; Watzka M; Sittinger K; Steffens M; Daugela L; Seifried E; Müller CR; Wienker TF; Oldenburg J
Thromb Haemost; 2005 Oct; 94(4):773-9. PubMed ID: 16270629
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients.
Shrif NE; Won HH; Lee ST; Park JH; Kim KK; Kim MJ; Kim S; Lee SY; Ki CS; Osman IM; Rhman EA; Ali IA; Idris MN; Kim JW
Eur J Clin Pharmacol; 2011 Nov; 67(11):1119-30. PubMed ID: 21590310
[TBL] [Abstract][Full Text] [Related]
7. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Rieder MJ; Reiner AP; Gage BF; Nickerson DA; Eby CS; McLeod HL; Blough DK; Thummel KE; Veenstra DL; Rettie AE
N Engl J Med; 2005 Jun; 352(22):2285-93. PubMed ID: 15930419
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing warfarin dose requirements in African-Americans.
Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
[TBL] [Abstract][Full Text] [Related]
10. VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications.
Suarez-Kurtz G; Amorim A; Damasceno A; Hutz MH; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Prata MJ; Ribeiro-dos-Santos A; Romano-Silva MA; Teixeira D; Struchiner CJ
Pharmacogenomics; 2010 Sep; 11(9):1257-67. PubMed ID: 20860466
[TBL] [Abstract][Full Text] [Related]
11. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Limdi NA; Wadelius M; Cavallari L; Eriksson N; Crawford DC; Lee MT; Chen CH; Motsinger-Reif A; Sagreiya H; Liu N; Wu AH; Gage BF; Jorgensen A; Pirmohamed M; Shin JG; Suarez-Kurtz G; Kimmel SE; Johnson JA; Klein TE; Wagner MJ;
Blood; 2010 May; 115(18):3827-34. PubMed ID: 20203262
[TBL] [Abstract][Full Text] [Related]
12. Genetic and clinical predictors of warfarin dose requirements in African Americans.
Cavallari LH; Langaee TY; Momary KM; Shapiro NL; Nutescu EA; Coty WA; Viana MA; Patel SR; Johnson JA
Clin Pharmacol Ther; 2010 Apr; 87(4):459-64. PubMed ID: 20072124
[TBL] [Abstract][Full Text] [Related]
13. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
Perera MA; Gamazon E; Cavallari LH; Patel SR; Poindexter S; Kittles RA; Nicolae D; Cox NJ
Clin Pharmacol Ther; 2011 Mar; 89(3):408-15. PubMed ID: 21270790
[TBL] [Abstract][Full Text] [Related]
14. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.
Veenstra DL; You JH; Rieder MJ; Farin FM; Wilkerson HW; Blough DK; Cheng G; Rettie AE
Pharmacogenet Genomics; 2005 Oct; 15(10):687-91. PubMed ID: 16141794
[TBL] [Abstract][Full Text] [Related]
15. Race influences warfarin dose changes associated with genetic factors.
Limdi NA; Brown TM; Yan Q; Thigpen JL; Shendre A; Liu N; Hill CE; Arnett DK; Beasley TM
Blood; 2015 Jul; 126(4):539-45. PubMed ID: 26024874
[TBL] [Abstract][Full Text] [Related]
16. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.
Ramirez AH; Shi Y; Schildcrout JS; Delaney JT; Xu H; Oetjens MT; Zuvich RL; Basford MA; Bowton E; Jiang M; Speltz P; Zink R; Cowan J; Pulley JM; Ritchie MD; Masys DR; Roden DM; Crawford DC; Denny JC
Pharmacogenomics; 2012 Mar; 13(4):407-18. PubMed ID: 22329724
[TBL] [Abstract][Full Text] [Related]
17. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
[TBL] [Abstract][Full Text] [Related]
18. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians.
Schelleman H; Chen Z; Kealey C; Whitehead AS; Christie J; Price M; Brensinger CM; Newcomb CW; Thorn CF; Samaha FF; Kimmel SE
Clin Pharmacol Ther; 2007 May; 81(5):742-7. PubMed ID: 17329985
[TBL] [Abstract][Full Text] [Related]
19. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.
Orsi FA; Annichino Bizzacchi JM; de Paula EV; Ozelo MC; Langley MR; Weck KE
Thromb Res; 2010 Sep; 126(3):e206-10. PubMed ID: 20615525
[TBL] [Abstract][Full Text] [Related]
20. Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.
Bargal SA; Kight JN; Augusto de Oliveira F; Shahin MH; Langaee T; Gong Y; Hamadeh IS; Cooper-DeHoff RM; Cavallari LH
Clin Transl Sci; 2021 Mar; 14(2):492-496. PubMed ID: 33278335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]